Cabaletta Bio said its Rezacel showed a favorable safety profile in the first 71 patients treated. Of the first six dermatomyositis patients past one year, 100% were off immunosuppressants. The company is running a pivotal myositis program in adults and children, and had about $300 million in cash at the end of the third quarter, spending $40 to $50 million per quarter.
CABA · Cabaletta Bio, Inc.
The latest filing states the doubt was alleviated.
“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 57%
- Last earnings
- Nov 10, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Cabaleta moved myositis BLA submission guidance to the first quarter of 28, alongside phase 1-2 data showing 94% of patients had no CRS or grade 1 CRS and 96% had no ICANs.
Cabaletta Bio, Inc. reported new Phase 1/2 rese-cel data: 100% (6/6) dermatomyositis patients sustained moderate-to-major responses through one year, 100% (5/5) biopsied lupus nephritis patients achieved DORIS remission, and 71% (5/7) systemic sclerosis patients achieved rCRISS-50.
Cabaletta Bio expects registrational myositis topline results in the second half of 2027 to support a potential BLA submission in the first quarter of 2028. It held $299.4 million in cash and cash equivalents as of September 30, 2026.
Cabaletta Bio plans a myositis BLA submission in 1Q28 after topline results in 2H27 and reported $299.4 million in cash as of September 30, 2026, extending its operational runway into 1Q28.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash from exercises of common stock warrants | $115M | July 1, 2026 to September 12, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CABA
this stock
Cabaletta Bio, Inc.
|
$201.94M | -57.3% | — | — | 17.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 27
Cabaletta Bio said its Rezacel showed a favorable safety profile in the first 71 patients treated. Of the first six dermatomyositis patients past one year, 100% were off immunosuppressants. The company is running a pivotal myositis program in adults and children, and had about $300 million in cash at the end of the third quarter, spending $40 to $50 million per quarter.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CABA | -26.9% | -36.3% | -74.6% | -38.0% | -57.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -18.3% | -27.1% | -65.4% | -29.3% | -58.4% |